Entera Bio (NASDAQ:ENTX – Get Free Report) and OSR (NASDAQ:OSRH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Entera Bio and OSR, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entera Bio | 1 | 0 | 4 | 1 | 2.83 |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
Entera Bio presently has a consensus target price of $9.60, suggesting a potential upside of 216.83%. Given Entera Bio’s stronger consensus rating and higher probable upside, research analysts clearly believe Entera Bio is more favorable than OSR.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entera Bio | $40,000.00 | 13,174.44 | -$11.44 million | ($0.35) | -8.66 |
| OSR | $1.81 million | 3.03 | -$27.06 million | ($0.37) | -0.42 |
Entera Bio has higher earnings, but lower revenue than OSR. Entera Bio is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Entera Bio has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Profitability
This table compares Entera Bio and OSR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entera Bio | N/A | -147.19% | -103.22% |
| OSR | -593.15% | -8.36% | -6.24% |
Insider and Institutional Ownership
14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 3.7% of Entera Bio shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Entera Bio beats OSR on 9 of the 15 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
